Comparing video and face-to-face HPV education for women 18–24
The Effect of Delivering HPV Education Through Different Methods on Young Women's Intention to Receive the Vaccine: A Randomized Controlled Trial
This project will test whether watching a pre-recorded video or attending an in-person education session helps women aged 18–24 better understand HPV and be more likely to get the HPV vaccine.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 117 (estimated) |
| Ages | 18 Years to 24 Years |
| Sex | Female |
| Sponsor | Kahramanmaras Sutcu Imam University Academic / other |
| Locations | 1 site (Kahramanmaraş) |
| Trial ID | NCT07420556 on ClinicalTrials.gov |
What this trial studies
This is a randomized controlled intervention enrolling women aged 18–24 registered at Family Health Centers in Afşin, Kahramanmaraş. Participants are randomly assigned to one of three groups: video-based education, face-to-face education, or a no-education control. HPV knowledge and vaccination intention are measured with a pre-test, an immediate post-test, and a one-month follow-up using standardized questionnaires. Educational materials follow national health guidelines and data will compare short-term and 1-month persistence of effects between delivery methods.
Who should consider this trial
Good fit: Women aged 18–24 who live in the Afşin district, read Turkish, have not received any HPV vaccine dose, and can attend the baseline, immediate post-education, and one-month follow-up visits.
Not a fit: Women who have already received or started the HPV vaccine series, have a prior HPV diagnosis, are outside the 18–24 age range, or cannot attend all sessions are unlikely to benefit from this intervention.
Why it matters
Potential benefit: If successful, the education approaches could raise HPV knowledge and increase vaccination intention and uptake among young women in the community.
How similar studies have performed: Previous studies have shown that educational interventions—both video and face-to-face—can improve HPV knowledge and vaccination intention, but effect size and durability vary by population and delivery method.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: Participants must meet all of the following criteria to be included in the study: Aged 18-24 years, Residing in Afşin district, Kahramanmaraş province, Willing to voluntarily participate in the study, Literate and able to understand survey questions in Turkish, Have not previously received the HPV vaccine, Agree to be available throughout the study period (pre-test, post-education test, and 1-month follow-up test), Young women without physical or cognitive impairments or serious health problems that would prevent participation in the study. Exclusion Criteria: Participants will be excluded if they meet any of the following conditions: Under 18 or over 24 years of age, Have received the HPV vaccine or started the vaccine series, Have been diagnosed with HPV infection, Unable to attend the educational sessions or complete all stages of data collection (pre-test, post-education test, 1-month follow-up test), Illiterate or unable to understand the study forms in Turkish, Withdraw from the study or indicate unwillingness to continue participation, Have serious hearing, vision, or cognitive impairments that would prevent meaningful engagement in the educational sessions.
Where this trial is running
Kahramanmaraş
- Afşin Aile Sağlığı Merkezleri — Kahramanmaraş, Turkey (Türkiye) (Recruiting)
Study contacts
- Study coordinator: Emel Asst. Prof.
- Email: emel_guclu4606@hotmail.com
- Phone: 03443004913
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.